Repurposing Approved Immunomodulatory Drugs for Target Proteins in the Pancreas of European eel: A Molecular Docking Approach

Year : 2025 | Volume : 03 | Issue : 01 | Page : 12-19
    By

    Varalakshmi T.S.,

  1. Student, Department of Bioinformatics, BioNome, Bangalore, Karnataka, India

Abstract

Leishmaniasis is a disease caused by tiny parasites called Leishmania, which spread to humans through the bite of an infected female sand fly. The disease manifests in three different forms, and the protein calcitonin promotes the disease’s spread. By reducing blood calcium levels, inhibiting osteoclast activity, increasing calcium excretion, and possibly playing a role in neurotransmitter modulation, calcitonin, a hormone released by vertebrates, promotes the progression of pathogenesis and lessens the load for parasites. The goal of the current investigation is to identify immunomodulatory medications that target the calcitonin protein. Drug banks and PubChem provided information for the molecular docking process, PyRx handled the docking process, and Biovia handled visualization, protein-ligand defining and the acquisition of 3D and 2D structures. To analyze protein flexibility, identify structural errors, and validate protein structure predictions, a Ramachandran plot was constructed, and other tools were used for pharmacological studies. Finally, Eplerenone and Saxagliptin are the two candidates selected as potential drugs to treat the leishmaniasis. Both Eplerenone and Saxagliptin help in reducing the spreading of leishmaniasis by binding to the calcitonin protein present in humans, which alters the immune responses in the body.

Keywords: Biovia discovery studio, CD4 T-cell, CD8 T-cell, drug bank database, food and drug administration, immunomodulatory drugs, PyRx, Ramachandran plot

[This article belongs to International Journal of Molecular Biotechnological Research ]

How to cite this article:
Varalakshmi T.S.. Repurposing Approved Immunomodulatory Drugs for Target Proteins in the Pancreas of European eel: A Molecular Docking Approach. International Journal of Molecular Biotechnological Research. 2025; 03(01):12-19.
How to cite this URL:
Varalakshmi T.S.. Repurposing Approved Immunomodulatory Drugs for Target Proteins in the Pancreas of European eel: A Molecular Docking Approach. International Journal of Molecular Biotechnological Research. 2025; 03(01):12-19. Available from: https://journals.stmjournals.com/ijmbr/article=2025/view=198106



Browse Figures

References

  1. Khadir F, Shaler CR, Oryan A, Rudak PT, Mazzuca DM, Taheri T, et al. Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin. PLoS Neglected Tropical Diseases. 2018 Aug 22;12(8):e0006701.
  2. Parizi MH, Sharifi I, Farajzadeh S, Pardakhty A, Parizi MH, Sharifi H, et al. Tioxolone niosomes exert antileishmanial effects on Leishmania tropica by promoting promastigote apoptosis and immunomodulation. Asian Pacific Journal of Tropical Medicine. 2019 Aug 1;12(8):365–74.
  3. Oualha R, Abdelkrim YZ, Guizani I, Harigua-Souiai E. Approved drugs successfully repurposed against Leishmania based on machine learning predictions. Frontiers in Cellular and Infection Microbiology. 2024 Sep 26;14:1403589.
  4. Dinc R. New developments in the treatment of cutaneous leishmaniasis. Asian Pacific Journal of Tropical Medicine. 2022 May 1;15(5):196–205.
  5. Nieva CB, Cid AG, Romero AI, García-Bustos MF, Villegas M, Bermúdez JM. An appraisal of the scientific current situation and new perspectives in the treatment of cutaneous leishmaniasis. Acta Tropica. 2021 Sep 1;221:105988.
  6. Charlton RL, Rossi-Bergmann B, Denny PW, Steel PG. Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art. Parasitology. 2018 Feb;145(2):219–36.
  7. Braga SS. Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing. Eur J Med Chem. 2019 Dec 1;183:111660.
  8. Jain S, Sahu U, Kumar A, Khare P. Metabolic pathways of Leishmania parasite: Source of pertinent drug targets and potent drug candidates. Pharmaceutics. 2022 Jul 30;14(8):1590.
  9. Palić S, Bhairosing P, Beijnen JH, Dorlo TP. Systematic review of host-mediated activity of miltefosine in leishmaniasis through immunomodulation. Antimicrobial Agents and Chemotherapy. 2019 Jul;63(7):10–128.
  10. Gupta R, Kushawaha PK, Samant M, Jaiswal AK, Baharia RK, Dube A. Treatment of leishmania donovani-infected hamsters with miltefosine: Analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses. J. Antimicrob Chemother. 2012 Feb 1;67(2):440–3.
Regular Issue Subscription Original Research
Volume 03
Issue 01
Received 27/12/2024
Accepted 11/01/2025
Published 12/02/2025
Publication Time 47 Days
Total Visits: 56


My IP

PlumX Metrics